title: Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.
authors.forename: Manuel
authors.initials: M
authors.lastname: Ramos-Casals
authors.forename: Candido
authors.initials: C
authors.lastname: Díaz-Lagares
authors.forename: Munther A
authors.initials: MA
authors.lastname: Khamashta
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000473:pathology; D008212:Lymphocyte Depletion; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab